Sage sacks staff as FDA miss makes slower growth more likely

Reeling from a  regulatory setback last month, Sage Therapeutics (Nasdaq: SAGE) is to undergo a major restructuring in the run-up to its launch of postpartum depression drug Zurzuvae (zuranolone).

The East Coast, USA-based company secured approval for Zurzuvae for adults with postpartum depression (PPD) last month, but missed out on the much larger indication of major depressive disorder (MDD).

Analysts have forecast that approval in MDD could make Zurzuvae a future blockbuster product, while PPD is expected to lead to up to half a billion dollars in peak revenues.